Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the target of a significant drop in short interest in October. As of October 15th, there was short interest totalling 4,000 shares, a drop of 13.0% from the September 30th total of 4,600 shares. Based on an average daily volume of 29,200 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the shares of the stock are sold short.

Institutional Trading of Barinthus Biotherapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Alphabet Inc. acquired a new position in shares of Barinthus Biotherapeutics during the 2nd quarter worth approximately $2,119,000. M&G Plc bought a new position in shares of Barinthus Biotherapeutics during the second quarter worth approximately $7,276,000. Catalina Capital Group LLC acquired a new stake in shares of Barinthus Biotherapeutics during the second quarter worth $25,000. Ipswich Investment Management Co. Inc. bought a new stake in Barinthus Biotherapeutics in the 2nd quarter valued at about $32,000. Finally, BlueCrest Capital Management Ltd acquired a new stake in Barinthus Biotherapeutics during the first quarter worth approximately $1,292,000. Institutional investors own 25.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Alliance Global Partners reduced their target price on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Barinthus Biotherapeutics in a research report on Thursday, September 26th.

Barinthus Biotherapeutics Price Performance

Shares of BRNS traded up $0.05 during mid-day trading on Thursday, hitting $1.48. 20,522 shares of the company’s stock were exchanged, compared to its average volume of 23,891. The company has a 50-day simple moving average of $1.27 and a 200 day simple moving average of $1.62. The company has a market cap of $58.33 million, a PE ratio of -0.87 and a beta of -0.53. Barinthus Biotherapeutics has a 52 week low of $1.11 and a 52 week high of $5.10.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its earnings results on Thursday, August 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.01). On average, analysts anticipate that Barinthus Biotherapeutics will post -1.71 earnings per share for the current year.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.